Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML less than or equal to 60 Years of Age

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML less than or equal to 60 Years of Age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Cytarabine; Daunorubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms SORAML

Most Recent Events

  • 01 Sep 2021 Results assessing to obtain additional data on the clinical course of patients in order to investigate the type and efficacy of second-line treatment in relapsed patients, including rates and modalities of allogeneic stem cell transplantation (allo SCT), cumulative incidence of relapse (CIR) from second complete remission (CR), and survival from first relapse, published in the Leukemia.
  • 12 Dec 2017 Long term follow-up results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
  • 05 Nov 2015 Final results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top